Tesaro CEO Lonnie Moulder may not have landed the deal he originally wanted for selling the biotech, but he’s not exactly coming away empty-handed.
As part of their detailed look back at the deal, the biotech also revealed that Moulder will receive a total of $155,854,551 for his stock, options and RSU grant. President Mary Lynne Hedley gets $112,500,429.
That’s all substantially better than the rest of the executive crew, each of whom gets millions. Here’s the full roster from the SEC filing.
- Timothy Pearson, CFO: $11.8 million
- Grant Bogle, chief commercial officer: $5.3 million
- Joseph Farmer, general counsel: $6.1 million
- Martin Huber, chief medical officer: $7 million
- Orlando Oliveira, general manager, international: $6 million
The top investor on Tesaro’s board was NEA, represented by David Mott, which gets $783 million in the buyout. Kleiner Perkins, which was represented by Beth Seidenberg, bags $167 million.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,400+ biopharma pros who read Endpoints News by email every day.Free Subscription